Technical Data
O7030-25A
OPRK1 (Kappa-type Opioid Receptor, K-OR-1, KOR-1, OPRK, Opioid Receptor, kappa)
Description:
G protein-coupled receptors (GPCRs) are the largest family of membrane receptors that activate intracellular signaling cascades and undergo endocytosis, recycling, or degradation upon stimulation. The mu, delta and kappa opioid receptors are GPCRs of the nervous system, which control pain, stress, and addictive behaviors. The kappa opioid receptor (KOR-1) plays a role in arousal and regulation of autonomic and neuroendocrine functions and is the receptor for dynorphins. KOR-1 inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance.

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1:500-1:1000
Optimal dilutions to be determined by the researcher.

Positive Control:
Human and rat brain lysate

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanRabbit
Concentration:
~1mg/ml
Immunogen:
Synthetic peptide corresponding to aa366-380 [DPAYLRDIDGMNLPV] of the human KOR-1 protein.
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in PBS, 0.02% sodium azide.
Specificity:
Recognizes human KOR-1. Species sequence homology: 66% in mouse and rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Simonin, F., Gaveriaux-Ruff, C., Befort, K., Matthes, H., Lannes, B., Micheletti, G., Mattei, M.G., Charron, G., Bloch, B. and Kieffer, B. kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc. Natl. Acad. Sci. U.S.A. 92(15), 7006-7010 (1995). 2. Bruchas, M.R., Yang, T., Schreiber, S., Defino, M., Kwan, S.C., Li, S. and Chavkin, C. Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J. Biol. Chem. 282(41), 29803-29811 (2007).